Genomic data encompasses information related to the structure, function, and variation within an organism's genome. It forms the foundation of precision medicine, from identifying disease-causing variants to stratifying patients for genetically targeted therapies. But as the volume of this data grows, so do the challenges of storing, analyzing, and making it accessible across research programs.
The global focus around COVID-19 has shifted from acute infections to the lingering challenge posed by long COVID, a condition where signs and symptoms persist well beyond the initial infection. Long COVID is now classified as an infection-associated chronic condition (IACC), placing it alongside other post-infectious syndromes such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and postural orthostatic tachycardia syndrome (POTS).
Genetic testing is now embedded across a wide range of clinical applications, from diagnosing neurocognitive disorders in children to guiding cancer treatment in adults. But as genomic technologies advance and testing volumes grow, a critical challenge intensifies: interpreting genetic results accurately. This challenge affects healthcare providers and patients alike, and the consequences of getting it wrong are significant.
This webinar featuring Mina Frost, General Counsel for Sano Genetics, provides an insightful overview of the legal and ethical intricacies involved in precision medicine. Mina expertly explores the complexities of patient privacy, data protection, and the regulatory landscape that govern precision medicine.
Recently, our team had the pleasure of attending the 16th Annual Patient Recruitment and Retention Summit, a hallmark event in the field of clinical research and patient advocacy. Hosted in an intimate, knowledge-sharing environment, this summit brought together experts from across the globe to share insights, strategies, and innovations aimed at enhancing patient involvement in clinical research. We were proud to sponsor a booth, which served as a hub for discussions, networking, and sharing our contributions to the field. In this blog, we’ll share the themes that rose to the top in our discussions.
In observance of Rare Disease Day, our latest episode of the Genetics Podcast presents a fascinating conversation with John Matthews, who was recently promoted to Chief Medical Officer at ReCode Therapeutics. This special episode not only commemorates the day dedicated to raising awareness for rare diseases but also showcases the innovative strides being made in the field of genetic medicine for the diagnosis and treatment of rare diseases.
In our latest whitepaper, "Beyond the bench: The role of patient empowerment in shaping precision medicine research," we examine how patient involvement is transforming the field of genomics- and biomarker-driven research. In highlighting the shift towards patient-centric models, we emphasise the importance of including patient insights in the development of new treatments.
In today's digital age, scientists and medical professionals are harnessing the power of healthcare data to unravel the genetic foundations of various diseases. But despite the growing portfolio of precision medicines, their integration into healthcare systems is not without its hurdles. This blog explores the challenges and opportunities of integrating precision medicine into healthcare systems.
Precision medicine is an approach to treatment and prevention that accounts for individual differences in genes, environment, and lifestyle. It represents a shift away from one-size-fits-all care toward decisions shaped by a patient's specific biology. Yet achieving health equity, in which every individual has the chance to attain their highest level of health regardless of background, remains a fundamental and unmet goal. Despite the promise of precision medicine, healthcare systems globally face significant challenges in providing equal access to these advances across all communities.
Parkinson's disease affects an estimated one to two percent of the population over the age of sixty, though the true prevalence is likely higher. As the research landscape evolves, the most consequential advances are those that connect basic science to actionable clinical strategy, particularly in genetics, biomarkers, and patient identification.